GLP-1 Medications and Heart Health: The Cardiovascular Benefits Beyond Weight Loss

When the SELECT trial results were published in late 2023, they changed the conversation about GLP-1 medications overnight. For the first time, a weight loss medication demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE) — heart attacks, strokes, and cardiovascular death.

This wasn't a small effect. It was a 20% relative risk reduction. And it appears to be at least partially independent of weight loss itself.

The SELECT trial: key findings

The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial was massive:

• 17,604 participants aged 45+ with BMI ≥27 and established cardiovascular disease
• No diabetes requirement — this was specifically a cardiovascular outcomes trial in people with obesity
• Median follow-up: 39.8 months — long enough to capture meaningful events
• Primary endpoint: 20% reduction in MACE (HR 0.80, 95% CI 0.72-0.90, p<0.001)

Beyond weight: direct cardiovascular effects

The cardiovascular benefit of GLP-1s appears to operate through multiple mechanisms beyond weight loss:

Blood pressure effects

GLP-1 medications produce modest but consistent blood pressure reductions: typically 3-6 mmHg systolic and 1-3 mmHg diastolic. While this seems small, population-level modeling suggests that a 5 mmHg systolic reduction decreases stroke risk by ~14% and coronary events by ~9%.

The mechanism is partly natriuretic (increased sodium excretion) and partly through weight loss itself, which reduces vascular resistance.

Heart failure: the STEP-HFpEF data

In 2024, the STEP-HFpEF trial showed that semaglutide significantly improved symptoms, physical limitations, and exercise function in patients with heart failure with preserved ejection fraction (HFpEF) — a condition with few effective treatments. This has opened an entirely new therapeutic application.

Who benefits most?

Based on the SELECT data, the cardiovascular benefit appears strongest in:

• Patients with established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• Those with multiple metabolic risk factors (hypertension + dyslipidemia + obesity)
• Patients with elevated hs-CRP (suggesting ongoing inflammation)

For patients without established cardiovascular disease, the weight loss and metabolic improvements are still beneficial, but the absolute risk reduction is smaller.

The reclassification of obesity medicine

SELECT fundamentally changed how we think about weight loss treatment. A medication that reduces cardiovascular events by 20% isn't a "cosmetic" treatment — it's a cardiovascular intervention. This has implications for insurance coverage, clinical guidelines, and how physicians counsel patients about the risk-benefit calculus.

If you have cardiovascular risk factors alongside overweight or obesity, a clinical evaluation is worth pursuing — not just for weight loss, but for heart protection.

Reviewed by Dr. Rachel Morrison, MD, ABOM. Updated July 2026. This article summarizes published clinical trial data and does not constitute medical advice. Discuss cardiovascular risk management with your physician.